Ample Stock Impacts Ritonavir’s Downstream Inquiries Across the Globe

The Global Ritonavir prices decreased during the month of February 2023 due to adequate product availability and lower requests among suppliers and retailers. Further currency devaluation, surplus supplies, and a lower trade environment reinforced the overall trend of Ritonavir worldwide.

In various regions, primarily in the United States, prices for Ritonavir were assessed to be on the lower side amid limited trade activity and a narrowing demand within its domestic market. In order to destock the aggregate stocks and balance their profit margins, the domestic suppliers lowered their selling prices. Besides this, February’s market in Europe has been dominated by product surplus, so the transactions by the traders to lower further quotations from exporting countries like India were unavoidable due to a negative demand.

Likewise, in India, one of the major exporters of Ritonavir to other regions, prices dropped throughout the mid of the first quarter of 2023. The purchasing pulse was noticeably stated to be on the weak side as buyers adopted a wait-and-see attitude to comprehend the overall market prognosis for downstream Ritonavir. However, the depreciation of the Indian Rupee (INR) this week led to decreased local and international prices for Ritonavir, which benefited other countries. In addition, market experts claim ample supplies are in circulation, but the recovery of downstream industry demand for this product from both the domestic and oversea markets has been slower than expected.

As per the ChemAnalyst, “the prices of Ritonavir expected to follow a similar trend in the forthcoming months, i.e., during March 2023. Market players might procure their shelves for Ritonavir on a need basis as the inventory level is projected to remain adequate to cope with the downstream demand. Trading activity across the nation is likely to stay on a lower end as the inquiries from the international market might continue to decrease.”